BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

888 related articles for article (PubMed ID: 21371705)

  • 21. Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support.
    Imbar T; Kol S; Lossos F; Bdolah Y; Hurwitz A; Haimov-Kochman R
    Hum Reprod; 2012 Mar; 27(3):753-9. PubMed ID: 22252086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol.
    Chen SL; Ye DS; Chen X; Yang XH; Zheng HY; Tang Y; He YX; Guo W
    Hum Reprod; 2012 May; 27(5):1351-6. PubMed ID: 22419746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study.
    Schachter M; Friedler S; Ron-El R; Zimmerman AL; Strassburger D; Bern O; Raziel A
    Fertil Steril; 2008 Oct; 90(4):1087-93. PubMed ID: 18023439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.
    Griesinger G; Diedrich K; Devroey P; Kolibianakis EM
    Hum Reprod Update; 2006; 12(2):159-68. PubMed ID: 16254001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
    Radesic B; Tremellen K
    Hum Reprod; 2011 Dec; 26(12):3437-42. PubMed ID: 21997895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cryopreserved blastocyst transfer: impact of gonadotropin-releasing hormone agonist versus antagonist in the previous oocyte retrieval cycles.
    Lee JR; Choi YS; Jee BC; Ku SY; Suh CS; Kim KC; Lee WD; Kim SH
    Fertil Steril; 2007 Nov; 88(5):1344-9. PubMed ID: 17548083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.
    Acevedo B; Gomez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2006 Dec; 86(6):1682-7. PubMed ID: 17074344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
    Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
    Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
    Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
    Yılmaz N; Ceran MU; Ugurlu EN; Gülerman HC; Engin Ustun Y
    J Obstet Gynaecol; 2020 Aug; 40(6):837-842. PubMed ID: 31791167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
    Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GnRH antagonist rescue of a short-protocol IVF/ICSI cycle and GnRH agonist triggering to prevent ovarian hyperstimulation syndrome: two case reports.
    Bakas P; Boutas I; Giner M; Panagopoulos P; Aravantinos L
    Clin Exp Obstet Gynecol; 2017; 44(2):279-282. PubMed ID: 29746040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New algorithm for OHSS prevention.
    Papanikolaou EG; Humaidan P; Polyzos N; Kalantaridou S; Kol S; Benadiva C; Tournaye H; Tarlatzis B
    Reprod Biol Endocrinol; 2011 Nov; 9():147. PubMed ID: 22054506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.